Dave Wallace, Generics Bulletin executive editor

Generics Bulletin editor Dave Wallace looks at everything that's important to the generics, biosimilars and value-added medicines industries. All views my own.

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

https://t.co/eVapnHu6Io

[Generics bulletin @Genericbulletin]

Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount
https://t.co/fRmAduw6I1

[Generics bulletin @Genericbulletin]

Shortlist Unveiled For GGB Awards
https://t.co/cvLlCDiTVB

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

This week Generics Bulletin has published its annual Top 50 ranking by turnover of the world's leading generics and biosimilars players. You can read the first of our four articles here:

[Generics bulletin @Genericbulletin]

The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations
https://t.co/JGscZTPjTC

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

In this exclusive two-part interview, @Amgen's Chad Pettit, @AmgenBiosim commercial lead, talks to @Genericbulletin about the firm’s “unique perspective” on biosimilars, including how competition to Humira is expected to signal a major shift in the US biosimilars landscape.

[Generics bulletin @Genericbulletin]

Amgen Calls For Balance To Support Biosimilars
https://t.co/VkOeMIqePI

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, says AmerisourceBergen’s (@Healthcare_ABC’s) senior vice president for global emerging therapies and channel strategy, Beth McMahon.

[Generics bulletin @Genericbulletin]

Competition Intensifies As Access Increases For US Biosimilars
https://t.co/ZOC6Kaqi40

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

In an exclusive two-part interview, @SamsungBioepis development division leader Kyung-ah Kim and @biogen global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize on their launch of the world’s first Lucentis biosimilar, Byooviz, in the US.

[Generics bulletin @Genericbulletin]

Supply Security And Competitive Pricing Will Support Byooviz Launch In US
https://t.co/o0E9MTV0CI

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

In this two-part interview, I talk to @hikmapharma CEO Siggi Olafsson about how Hikma expects to maintain its deal-making momentum, future plans for US biosimilars, and how it is positioned to deal with pricing pressures and increased competition on some of its key generics.

[Generics bulletin @Genericbulletin]

Hikma Has An Appetite For More Deals As It Builds On Acquisitions
https://t.co/nzih7xAS6u

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

Sonia Oskouei, @cardinalhealth VP of biosimilars, talks about how real-world evidence and education can build confidence in biosimilars, as well as the ongoing struggle against misinformation and need for clarity over concepts such as interchangeability and unbranded biologics.

[Generics bulletin @Genericbulletin]

Evidence And Education Must Support US Biosimilars
https://t.co/zAgxA8bVcm

[AAM @AccessibleMeds]

In this @Pharma_Intell interview, #AAMBoard Vice Chair Christine Baeder (Senior Vice President, Chief Operating Officer for US Generics @TevaUSA) explores the challenges and opportunities of #ComplexGenerics.
Read: https://t.co/WqyD3cOWz5

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

A major biosimilars deal between @Bioconlimited and @ViatrisInc to kick off this week:

[Generics bulletin @Genericbulletin]

Biocon Pays $3.3bn For Viatris Biosimilars Business
https://t.co/cgs8rl0cFd

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

With key milestones on the horizon for US biosimilars in 2022 and 2023, @cardinalhealth VP of biosimilars Sonia Oskouei explains how the industry can best position itself to take advantage of upcoming opportunities, including potentially a global leadership role in ophthalmology.

[Generics bulletin @Genericbulletin]

US Has Opportunity To Lead On Ophthalmic Biosimilars
https://t.co/w3Ec0Va8P6

[Biosimilars Forum @USBiosimilars]

Biosimilars Forum executive director Juliana Reed discusses the Forum's priorities and leadership in the #biosimilars industry in an interview with @DaveGenerics @Genericbulletin Read more here: https://t.co/KMMXOKUnmt

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

In an exclusive interview with Generics Bulletin, the @USBiosimilars Forum’s executive director Julie Reed sets out the group’s priorities and explains how its diverse membership is helping to position it as a leading voice for the US biosimilars industry.

[Generics bulletin @Genericbulletin]

Reed Sets Out Priorities For US Biosimilars Forum
https://t.co/iUFN4aCg3e

[Róbert Wessman @RobertWessman]

This is the first part of an exclusive two-part interview with David Wallace at @Genericbulletin, where I talk about Alvotech’s plans to move forward following the SPAC merger, partnerships, and strategy on our biosimilars journey. https://t.co/BIdmfAKnZt

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

In the second part of an exclusive two-part interview with Generics Bulletin, @alvotechpr founder and chairman @RobertWessman sets out the firm’s expectations for its rival to Humira as it continues to battle AbbVie in US litigation over its higher-strength adalimumab biosimilar.

[Generics bulletin @Genericbulletin]

Alvotech Could Upend Expectations For US Humira Biosimilars
https://t.co/EuEgLj4QYD

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

Alvotech founder and chairman @RobertWessman tells Generics Bulletin how the firm plans to move forward following recently-revealed plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. @alvotechpr

[Generics bulletin @Genericbulletin]

Alvotech’s Wessman Sets Out Next Steps On Biosimilars Journey
https://t.co/QrAquJiGGy

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

With the first approved rival to Lucentis in both the EU and US, @SamsungBioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.

[Generics bulletin @Genericbulletin]

How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars
https://t.co/n4BW4gBqWS

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

With the Big Give, @ihp_uk is raising money to get vital medicine to people who need it. For every £1 donated, IHP can send £20 worth of medicine. https://t.co/7OUni0VRNC

https://t.co/iWagGz04YV

[International Health Partners @ihp_uk]

The @BigGive #ChristmasChallenge21 ends in 24 hours. We still have about £10,000 of match funding still available! We need your help urgently to make double the difference to the lives of people who lack access to medicine around the world: https://t.co/iRzOa3jFEy

[Dave Wallace, Generics Bulletin executive editor @DaveGenerics]

In this interview, CEO Michael Goettler provides an update on the progress made by @ViatrisInc in its first year, also previewing the detailed strategy that will be unveiled at the firm’s upcoming investor day and underlining the importance of biosimilars and complex generics.

[Generics bulletin @Genericbulletin]

Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars
https://t.co/4wXQyfyY15

[International Health Partners @ihp_uk]

Thanks for a great night at the #GGBAwards. A big shout out to all the entries for this year’s #CSR Initiative of the Year award. It’s so encouraging to see all the great work the Generics sector is doing to support people in need. @Genericbulletin @DaveGenerics